JP6143877B2 - ２−アリールセレナゾール化合物及びその薬剤組成物 - Google Patents

２−アリールセレナゾール化合物及びその薬剤組成物 Download PDF

Info

Publication number
JP6143877B2
JP6143877B2 JP2015544335A JP2015544335A JP6143877B2 JP 6143877 B2 JP6143877 B2 JP 6143877B2 JP 2015544335 A JP2015544335 A JP 2015544335A JP 2015544335 A JP2015544335 A JP 2015544335A JP 6143877 B2 JP6143877 B2 JP 6143877B2
Authority
JP
Japan
Prior art keywords
methyl
selenazole
formic acid
cyano
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015544335A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016500115A (ja
JP2016500115A5 (OSRAM
Inventor
史▲東▼方
▲伝長▼金
▲呉▼捷
▲劉▼俊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atom Therapeutics Co Ltd
Original Assignee
Atom Bioscience and Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atom Bioscience and Pharmaceutical Co Ltd filed Critical Atom Bioscience and Pharmaceutical Co Ltd
Publication of JP2016500115A publication Critical patent/JP2016500115A/ja
Publication of JP2016500115A5 publication Critical patent/JP2016500115A5/ja
Application granted granted Critical
Publication of JP6143877B2 publication Critical patent/JP6143877B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D293/00—Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms
    • C07D293/02—Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms not condensed with other rings
    • C07D293/04—Five-membered rings
    • C07D293/06—Selenazoles; Hydrogenated selenazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D421/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms
    • C07D421/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings
    • C07D421/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D421/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms
    • C07D421/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings
    • C07D421/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2015544335A 2012-11-30 2013-11-24 ２−アリールセレナゾール化合物及びその薬剤組成物 Expired - Fee Related JP6143877B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201210504310.8 2012-11-30
CN201210504310.8A CN103848798B (zh) 2012-11-30 2012-11-30 2-芳基硒唑化合物及其药物组合物
PCT/CN2013/087736 WO2014082548A1 (zh) 2012-11-30 2013-11-24 2-芳基硒唑化合物及其药物组合物

Publications (3)

Publication Number Publication Date
JP2016500115A JP2016500115A (ja) 2016-01-07
JP2016500115A5 JP2016500115A5 (OSRAM) 2017-05-18
JP6143877B2 true JP6143877B2 (ja) 2017-06-07

Family

ID=50827179

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015544335A Expired - Fee Related JP6143877B2 (ja) 2012-11-30 2013-11-24 ２−アリールセレナゾール化合物及びその薬剤組成物

Country Status (5)

Country Link
US (1) US9802907B2 (OSRAM)
EP (1) EP2927219B1 (OSRAM)
JP (1) JP6143877B2 (OSRAM)
CN (1) CN103848798B (OSRAM)
WO (1) WO2014082548A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103936693B (zh) * 2013-01-22 2016-06-15 沈阳药科大学 2-(3-氰基-4-取代苯基)-4-甲基-1,3-硒唑-5-甲酸及其酯类化合物和制备方法
CN108358866B (zh) * 2017-01-12 2021-03-23 江西同和药业股份有限公司 一种非布司他中间体的制备方法及其在制备非布司他中的应用
CN111662239B (zh) * 2019-03-06 2023-07-28 中国医学科学院药物研究所 1,2,4-三唑类化合物及其制法和药物用途
CN113354616B (zh) * 2020-03-05 2024-03-26 中国医学科学院药物研究所 二芳基-1,2,4-三唑类化合物及其制法和药物用途
WO2022083687A1 (zh) * 2020-10-21 2022-04-28 南京明德新药研发有限公司 硒杂环类化合物及其应用
WO2023202706A1 (zh) * 2022-04-21 2023-10-26 南京明德新药研发有限公司 硒杂环类化合物的盐型和晶型及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2725886B2 (ja) * 1990-11-30 1998-03-11 帝人株式会社 ２―アリールチアゾール誘導体及びその医薬組成物
JP3113110B2 (ja) 1993-01-19 2000-11-27 帝人株式会社 イソキサゾールおよびイソチアゾール誘導体
CA2190993C (en) 1995-04-07 2004-06-01 Mikio Ota Protective agent for organ or tissue
ID21775A (id) 1996-10-25 1999-07-22 Yoshitomi Pharmaceutical Senyawa-senyawa 1-fenilpirazol dan penggunaan farmasinya
JPH10310578A (ja) 1996-11-13 1998-11-24 Yoshitomi Pharmaceut Ind Ltd ３−フェニルピラゾール化合物
JP2002105067A (ja) * 2000-09-28 2002-04-10 Teijin Ltd ２−フェニルチアゾール誘導体、およびそれを有効成分とする医薬組成物
EP1757610B1 (en) 2004-06-14 2011-06-08 Nippon Chemiphar Co., Ltd. Condensed pyrimidine derivative and xanthine oxidase inhibitor
JPWO2006022375A1 (ja) 2004-08-27 2008-05-08 アステラス製薬株式会社 ２−フェニルチオフェン誘導体
EP1783116B1 (en) 2004-08-27 2009-08-26 Astellas Pharma Inc. 2-phenylpyridine derivative
WO2007043457A1 (ja) * 2005-10-07 2007-04-19 Astellas Pharma Inc. トリアリールカルボン酸誘導体
CA2789458A1 (en) * 2010-02-25 2011-09-01 Heonjoong Kang Selenalzole derivative having ligand which activates peroxisome proliferator activated receptor (ppar), preparing method thereof and usage of the chemical compounds
CN103130744B (zh) * 2012-08-28 2014-10-15 沈阳药科大学 一种硒唑甲酸类化合物及其制备方法和用途

Also Published As

Publication number Publication date
US20150291543A1 (en) 2015-10-15
US9802907B2 (en) 2017-10-31
EP2927219A1 (en) 2015-10-07
EP2927219A4 (en) 2016-07-06
CN103848798A (zh) 2014-06-11
JP2016500115A (ja) 2016-01-07
CN103848798B (zh) 2016-01-06
EP2927219B1 (en) 2018-05-30
WO2014082548A1 (zh) 2014-06-05

Similar Documents

Publication Publication Date Title
JP6143877B2 (ja) ２−アリールセレナゾール化合物及びその薬剤組成物
JP6635527B2 (ja) 高尿酸血症又は痛風の治療又は予防用化合物
JP2006517199A5 (OSRAM)
JP2010520303A (ja) Ｐｐａｒ活性化合物
JP2020503263A (ja) Ｕｒａｔ１抑制剤及びその使用
JP7713253B2 (ja) キサンチンオキシダーゼ抑制剤
CN103980267B (zh) 一类新型黄嘌呤氧化酶抑制剂的化合物及其药物组合物
CN106632245B (zh) 氮取代基苯基吡唑类黄嘌呤氧化还原酶抑制剂及制备与应用
TW201843135A (zh) 胺基-芳基-苯甲醯胺化合物及其使用方法
JPH08500101A (ja) 炎症抑制剤として有用な２−複素環−５−ヒドロキシ−１，３−ピリミジン類
JPS60163852A (ja) アナフイラキシーの遅反応物質の拮抗物質
EP0398179A1 (en) Rhodanine derivatives and pharmaceutical compositions
CN103848796A (zh) 一类氘代2-苯基噻唑化合物及其药物组合物
CN110483487B (zh) 一种2-硫甲基吡唑嘧啶酮类化合物、其制备方法、药物组合物及应用
KR102329486B1 (ko) 할로겐화 화합물 및 이의 축상 키랄성 이성질체
EP1666455A1 (en) Amide type carboxamide derivative
WO2020147803A1 (zh) 3-溴-5-(2-乙基咪唑并[1,2-a]吡啶-3-羰基)-2-羟基苯甲腈的合成
WO2020173417A1 (zh) 含丙烯酰基的核转运调节剂及其用途
CN110078668B (zh) 一种苯基咪唑类xor抑制剂及制备与应用
WO2021000527A1 (zh) 三环类xor抑制剂及其制备方法和应用
JP7450951B2 (ja) 新型ｆｘｒ小分子作動剤の製造およびその使用
JPH0672866A (ja) 分化誘導剤
CN108069940B (zh) 硫代乙酸化合物、组合物及其应用
CA2956464A1 (en) Bisamidinium-based inhibitors for the treatment of myotonic dystrophy
CN117203211B (zh) 咪唑并噻唑衍生物及其制备方法与应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150716

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160726

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20161017

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170117

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20170329

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170411

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170509

R150 Certificate of patent or registration of utility model

Ref document number: 6143877

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees